Business models for biomaterials in regenerative medicine.
The emergence of new therapeutic methods and technologies, including those associated with regenerative medicine, has required new thinking about regulation, reimbursement and business models. Some of the issues that particularly relate to the materials used in these technologies are discussed in this article.
Williams
David
D
Clinical Engineering Department, Royal Liverpool University Hospital, Liverpool, UK. dfw@ce@liverpool.ac.uk
D001672:Biocompatible Materials / Q000191:economics*; D005060:Europe; D005161:Facility Regulation and Control; D005376:Financial Management; D048091:Guided Tissue Regeneration / Q000191:economics*; D006801:Humans; D007753:Laboratories / Q000191:economics* / Q000458:organization & administration; D017149:Private Sector; D012051:Reimbursement Mechanisms; D023822:Tissue Engineering / Q000191:economics*
D001672:Biocompatible Materials